Garrisi Vito Michele, Abbate Ines, Quaranta Michele, Mangia Anita, Tommasi Stefania, Paradiso Angelo
Chemical-Clinical Microbiology and Immunology Laboratory Unit, 'Giovanni Paolo II', National Cancer Institute, Via Samuel F. Hahnemann 10, 70126 Bari, Italy.
Expert Rev Proteomics. 2008 Dec;5(6):779-85. doi: 10.1586/14789450.5.6.779.
Despite the efforts of recent years, clinicians still lack reliable biomarkers for diagnosis, prognosis and prediction of clinical outcomes in breast cancer patients. Owing to the large number of people potentially involved in the management of this clinical problem, the search for noninvasive and repeatable laboratory assays has been intensive. Recently, the proteomic profiling performed by SELDI-TOF mass spectrometry, has been proposed in order to identify new clusters of serum markers that could be potentially useful in breast cancer management. The purpose of this special report is to review the literature on SELDI-TOF technology applied on serum coming from healthy people and breast cancer patients, in order to verify the clinical applicability of such approach. We conclude that potential new biomarkers, first of all for early diagnosis of breast cancer, need to be validated in larger clinical series.
尽管近年来已付出诸多努力，但临床医生仍缺乏用于乳腺癌患者诊断、预后评估及临床结局预测的可靠生物标志物。鉴于大量人员可能参与到这一临床问题的管理中，对非侵入性且可重复的实验室检测方法的探索一直很深入。最近，有人提出通过表面增强激光解吸电离飞行时间质谱（SELDI-TOF）进行蛋白质组分析，以识别可能对乳腺癌管理有潜在用途的新血清标志物群。本专题报告的目的是回顾关于SELDI-TOF技术应用于健康人和乳腺癌患者血清的文献，以验证该方法的临床适用性。我们得出结论，潜在的新生物标志物，首先是用于乳腺癌早期诊断的生物标志物，需要在更大规模的临床系列研究中进行验证。
